Dysplastic nevi and melanoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 4, 2013, Pages 528-532

  Goldstein, Alisa M ^a   Tucker, Margaret A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; INTERFERON REGULATORY FACTOR 4;

ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CHROMOSOME 7Q; CLINICAL EXAMINATION; DYSPLASTIC NEVUS; EPILUMINESCENCE MICROSCOPY; FAMILY HISTORY; FOLLOW UP; GENE LOCUS; GENE MUTATION; HEREDITY; HISTOLOGY; HUMAN; LENTIGO; MELANOMA; META ANALYSIS (TOPIC); MICROSATELLITE MARKER; PATIENT CARE; PRIORITY JOURNAL; RISK FACTOR; SCAR; SELF EVALUATION; SKIN DEFECT; SUNBURN; TUMOR GROWTH; ULTRAVIOLET RADIATION;

DISEASE PROGRESSION; DYSPLASTIC NEVUS SYNDROME; HUMANS; MELANOMA; RISK FACTORS;

EID: 84876547682     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-1346     Document Type: Article

References (45)

1. Clark WH Jr, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ. Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol 1978;114:732-8.
2. Frichot BC III, Lynch HT, Guirgis HA, Harris RE, Lynch JF. New cutaneous phenotype in familial malignant melanoma. Lancet 1977;1: 864-5.
3. Lynch HT, Frichot BC III, Lynch JF. Familial atypical multiple molemelanoma syndrome. J Med Genet 1978;15:352-6. (Pubitemid 9041252)
4. Elder DE. Dysplastic naevi: an update. Histopathology 2010;56: 112-20.
5. Elder DE, Goldman LI, Goldman SC, Greene MH, Clark WH Jr. Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer 1980;46:1787-94. (Pubitemid 10011134)
6. Greene MH, Clark WH Jr, Tucker MA, Elder DE, Kraemer KH, Fraser MC, et al. Precursor naevi in cutaneous malignant melanoma: a proposed nomenclature. Lancet 1980;2:1024. (Pubitemid 10025088)
7. Duffy K, Grossman D. The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects. J Am Acad Dermatol 2012;67:1e-16
8. Farber MJ, Heilman ER, Friedman RJ. Dysplastic nevi. Dermatol Clin 2012;30:389-404.
9. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005;41:28-44. (Pubitemid 40029657)
10. NIH Consensus conference. Diagnosis and treatment of early melanoma. JAMA 1992;268:1314-9.
11. Diagnosis and treatment of early melanoma. NIH Consensus Development Conference. January 27-29, 1992. NIH Consens Statement. 1992;10:1-26.
12. de Wit PE, van't Hof-Grootenboer B, Ruiter DJ, Bondi R, Brocker EB, Cesarini JP, et al. Validity of the histopathological criteria used for diagnosing dysplastic naevi. An interobserver study by the pathology subgroup of the EORTC Malignant Melanoma Cooperative Group. Eur J Cancer 1993;29A:831-9. (Pubitemid 23083611)
13. Hartge P, Holly EA, Halpern A, Sagebiel R, Guerry D, Elder D, et al. Recognition and classification of clinically dysplastic nevi from photographs: a study of interobserver variation. Cancer Epidemiol Biomarkers Prev 1995;4:37-40.
14. Piepkorn MW, Barnhill RL, Cannon-Albright LA, Elder DE, Goldgar DE, Lewis CM, et al. A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. J Am Acad Dermatol 1994;30: 707-14. (Pubitemid 24157110)
15. Rhodes AR, MihmMCJr, Weinstock MA. Dysplastic melanocytic nevi: a reproducible histologic definition emphasizing cellular morphology. Mod Pathol 1989;2:306-19.
16. Shapiro M, ChrenMM, LevyRM, Elder DE, LeBoit PE, MihmMCJr, et al. Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists. J Cutan Pathol 2004;31:523-30. (Pubitemid 39061800)
17. Steijlen PM, Bergman W, Hermans J, Scheffer E, Van Vloten WA, Ruiter DJ. The efficacy of histopathological criteria required for diagnosing dysplastic naevi. Histopathology 1988;12:289-300.
18. Weinstock MA, Barnhill RL, Rhodes AR, Brodsky GL. Reliability of the histopathologic diagnosis of melanocytic dysplasia. The Dysplastic Nevus Panel. Arch Dermatol 1997;133:953-8. (Pubitemid 27351866)
19. Tucker MA. Atypical melanocytic nevi (Chapter 123). In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, editors. Fitzpatrick's Dermatology in General Medicine, 7th edition. New York, NY: McGraw-Hill Companies; 2007.
20. Goldstein AM, Tucker MA. Genetic epidemiology of cutaneous melanoma: a global perspective. Arch Dermatol 2001;137:1493-6. (Pubitemid 33064245)
21. Tucker MA, Goldstein AM. Melanoma etiology: where are we? Oncogene 2003;22:3042-52.
22. Tucker MA. Melanoma epidemiology. Hematol Oncol Clin North Am 2009;23:383-95.
23. Law MH, Macgregor S, Hayward NK. Melanoma genetics: recent findings take us beyond well-traveled pathways. J Invest Dermatol 2012;132:1763-74.
24. Hayward NK. Genetics of melanoma predisposition. Oncogene 2003;22:3053-62. (Pubitemid 36713755)
25. Chang YM, Newton-Bishop JA, Bishop DT, Armstrong BK, Bataille V, Bergman W, et al. A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int J Cancer 2009;124:420-8.
26. Duffy DL, Zhao ZZ, Sturm RA, Hayward NK, Martin NG, Montgomery GW. Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J Invest Dermatol 2010;130:520-8.
27. Falchi M, Bataille V, Hayward NK, Duffy DL, Bishop JA, Pastinen T, et al. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet 2009;41:915-9.
28. Bishop JA, Wachsmuth RC, Harland M, Bataille V, Pinney E, Mac KP, et al. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J Invest Dermatol 2000; 114:28-33. (Pubitemid 30195968)
29. de Snoo FA, Hottenga JJ, Gillanders EM, Sandkuijl LA, Jones MP, Bergman W, et al. Genome-wide linkage scan for atypical nevi in p16- Leiden melanoma families. Eur J Hum Genet 2008;16:1135-41.
30. Nielsen K, Harbst K, Masback A, Jonsson G, Borg A, Olsson H, et al. Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype. Melanoma Res 2010;20:266-72.
31. Puig S, Ruiz A, Castel T, Volpini V, Malvehy J, Cardellach F, et al. Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene. Hum Genet 1997;101:359-64. (Pubitemid 28197534)
32. Chaudru V, Chompret A, Bressac-de Paillerets B, Spatz A, Avril MF, Demenais F. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanomaprone families. J Natl Cancer Inst 2004;96:785-95. (Pubitemid 38771824)
33. Chaudru V, Laud K, Avril MF, Miniere A, Chompret A, Bressac-de Paillerets B, et al. Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. Cancer Epidemiol Biomarkers Prev 2005;14:2384-90. (Pubitemid 41437841)
34. Goldstein AM, Falk RT, Fraser MC, Dracopoli NC, Sikorski RS, Clark WH Jr, et al. Sun-related risk factors in melanoma-prone families with CDKN2A mutations. J Natl Cancer Inst 1998;90:709-11. (Pubitemid 28222146)
35. Zhu G, Montgomery GW, James MR, Trent JM, Hayward NK, Martin NG, et al. A genome-wide scan for naevus count: linkage to CDKN2A and to other chromosome regions. Eur J Hum Genet 2007;15:94-102. (Pubitemid 44921672)
36. MedlinePlus (Merriam Webster) www.merriam-webster.com/medlineplus/ precursor.
37. Tucker MA, Fraser MC, Goldstein AM, Struewing JP, King MA, Crawford JT, et al. A natural history of melanomas and dysplastic nevi: an atlas of lesionsinmelanoma-pronefamilies.Cancer 2002;94:3192-209. (Pubitemid 34670503)
38. Halpern AC, Guerry Dt, Elder DE, Trock B, Synnestvedt M, Humphreys T. Natural history of dysplastic nevi. J Am Acad Dermatol 1993;29: 51-7. (Pubitemid 23197196)
39. Tsao H, Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a populationbased estimate. Arch Dermatol 2003;139:282-8. (Pubitemid 36330574)
40. Tucker MA, Halpern A, Holly EA, Hartge P, Elder DE, Sagebiel RW, et al. Clinically recognized dysplastic nevi.Acentral risk factor for cutaneous melanoma. JAMA 1997;277:1439-44. (Pubitemid 27208885)
41. Tucker MA, Fraser MC, Goldstein AM, Elder DE, Guerry Dt, Organic SM. Risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol 1993;100:350S-5S. (Pubitemid 23083198)
42. Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol 2008;159:669-76.
43. Kovalyshyn I, Dusza SW, Siamas K, Halpern AC, Argenziano G, Marghoob AA. The impact of physician screening on melanoma detection. Arch Dermatol 2011;147:1269-75.
44. Risser J, Pressley Z, Veledar E, Washington C, Chen SC. The impact of total body photography on biopsy rate in patients from a pigmented lesion clinic. J Am Acad Dermatol 2007;57:428-34. (Pubitemid 47239142)
45. Salerni G, Carrera C, Lovatto L, Puig-Butille JA, Badenas C, Plana E, et al. Benefits of total body photography and digital dermatoscopy ("two-step method of digital follow-up") in the early diagnosis of melanoma in patients at high risk for melanoma. J Am Acad Dermatol 2012;67:e17-27.